This is a demo store. No orders will be fulfilled.

Toggle Nav
My Cart
Search
Advanced Search
Menu
Account
Settings

Genetic Technology Alert. High-Priced Hepatitis C Drug Results in Development of Generic Products; FDA-Approved Rapid Antigen Test for Ebola; Focused Antiviral Clinical Programs for Infectious Diseases

Genetic Technology Alert. High-Priced Hepatitis C Drug Results in Development of Generic Products; FDA-Approved Rapid Antigen Test for Ebola; Focused Antiviral Clinical Programs for Infectious Diseases

RELEASE DATE
24-Jul-2015
REGION
Global
Deliverable Type
Technology Alert
Research Code: D757-00-05-00-00
SKU: HC02737-GL-TA_19631
$250.00
In stock
SKU
HC02737-GL-TA_19631
$250.00
DownloadLink
Add to Compare

Pay by invoice

ENQUIRE NOW

Description

This issue profiles a high-priced hepatitis c drug that results in development of generic products, a rapid antigen test for Ebola, and focused antiviral clinical programs for infectious diseases.

Table of Contents

In This Issue

  • 1. HIGH-PRICED HEPATITIS C DRUG RESULTS IN DEVELOPMENT OF GENERIC PRODUCTS
  • 2. FOCUSED ANTIVIRAL CLINICAL PROGRAMS FOR INFECTIOUS DISEASES
  • 3. FDA-APPROVED RAPID ANTIGEN TEST FOR EBOLA
  • 4. KEY PATENTS ACROSS THERAPEUTICS FOR INFECTIOUS DISEASES
  • 5. TECHVISION 2015
Request Sample
Popular Topics

health supplement market

virtual reality market

commercial aviation market

commercial lighting market

residential energy storage market

wearable electronics market

activated carbon market

well intervention market

emulsifier market

flexible electronics market

This issue profiles a high-priced hepatitis c drug that results in development of generic products, a rapid antigen test for Ebola, and focused antiviral clinical programs for infectious diseases.
More Information
Deliverable Types Technology Alert
No Index No
Podcast No
Industries Healthcare
WIP Number D757-00-05-00-00
Is Prebook No
Ti Codes D758